<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018091</url>
  </required_header>
  <id_info>
    <org_study_id>21081102</org_study_id>
    <nct_id>NCT05018091</nct_id>
  </id_info>
  <brief_title>Dexamethasone in Total Knee Arthroplasty</brief_title>
  <official_title>Dexamethasone in Total Knee Arthroplasty: What Dose Should we be Giving Patients Intraoperatively</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the most efficacious and safest dexamethasone dose&#xD;
      given intraoperatively during total knee arthroplasty that reduces postoperative opioid&#xD;
      consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative&#xD;
      complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: Prospective randomized controlled trial&#xD;
&#xD;
      Scientific Background: In contemporary total joint arthroplasty (TJA), multimodal anesthesia&#xD;
      and analgesia is used to improve postoperative pain, reduce opioid consumption, and minimize&#xD;
      complications after surgery such as postoperative nausea and vomiting.1-3 Multiple&#xD;
      medications with varying mechanisms of action are used at different time points throughout&#xD;
      the perioperative period to modulate different pain receptors. Corticosteroids are a&#xD;
      medication commonly utilized intraoperatively as part of contemporary multimodal protocols.&#xD;
&#xD;
      Corticosteroids are frequently used in TJA due to their potent anti-inflammatory and&#xD;
      anti-emetic properties. Several studies have demonstrated that corticosteroids reduce&#xD;
      postoperative nausea and vomiting as well as postoperative pain and opioid consumption.4-6&#xD;
      However, the optimal medication, dose, and number of doses of corticosteroid that should be&#xD;
      administered in the perioperative period remain unknown. In addition, it remains unclear if&#xD;
      corticosteroids can be safely used in patients with diabetes mellitus or if corticosteroids&#xD;
      increase the risk of postoperative complications such as periprosthetic joint infection.&#xD;
      Thus, the purpose of our study is to determine the most efficacious and safest dose of&#xD;
      corticosteroids that should be administered intraoperatively during TJA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>48-hours postoperative (after surgical intervention)</time_frame>
    <description>48 hours of cumulative opioid consumption measured in oral morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain scores at rest and with activity</measure>
    <time_frame>Immediately after surgical intervention (TKA) for days 1 through 7 after surgery</time_frame>
    <description>Using daily Defense and Veterans Pain Rating scale to rate pain at rest and with activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>Immediately after surgical intervention (TKA) for days 1 through 7 after surgery. Using numeric rating scale.</time_frame>
    <description>Using numeric rating scale, (1-10, where 10 is most nausea, causing vomiting followed by number of times participant vomited in 24-hour period).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Blood glucose levels and insulin use</measure>
    <time_frame>Immediately following surgical intervention until discharge from hospital (up to 30 days after surgery if still in hospital)</time_frame>
    <description>check glucose levels in daily blood draws when inpatient at hospital, insulin if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>immediately following surgery (intervention), number of days spent in the hospital after surgery to discharge, up to 30 days after intervention</time_frame>
    <description>Days inpatient at hospital after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleeplessness/insomnia</measure>
    <time_frame>Immediately after surgical intervention (TKA) for days 1 through 7 after surgery, recording 24 hour sleep patterns</time_frame>
    <description>recorded by patient, daily sleep schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with complications (such as readmission to hospital) up to 30 days after surgical intervention</measure>
    <time_frame>&lt;30 days after surgical intervention, document any readmissions to the hospital or complications that occur within 30 days from the day of surgery</time_frame>
    <description>Readmission after surgery, infection, VTE, GI hemorrhage or any other complication that requires rehospitalization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">429</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4mg intravenous dexamethasone, administered shortly after induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8mg intravenous dexamethasone, administered shortly after induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16mg intravenous dexamethasone, administered shortly after induction of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4mg</intervention_name>
    <description>4mg intravenous dexamethasone, administered shortly after induction of anesthesia</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 8 Mg/mL Injectable Suspension</intervention_name>
    <description>8mg intravenous dexamethasone, administered shortly after induction of anesthesia</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 16mg</intervention_name>
    <description>16mg intravenous dexamethasone, administered shortly after induction of anesthesia</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Group 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Primary total knee arthroplasty&#xD;
&#xD;
          -  Patients staying at least one night in the hospital after surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Same day discharge Age &lt; 18 years Revision or partial total knee arthroplasty&#xD;
             Corticosteroid use within 3 months prior to surgery Inflammatory arthritis Current&#xD;
             systemic fungal infection Renal or liver failure Prior adverse reaction to&#xD;
             corticosteroid Primary TKA requiring hardware removal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne DeBenedetti, BA</last_name>
    <phone>3124322468</phone>
    <email>anne.debenedetti@rushortho.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rush University medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DeBenedetti, BA</last_name>
      <phone>312-432-2468</phone>
      <email>anne.debenedetti@rushortho.com</email>
    </contact>
    <investigator>
      <last_name>Craig Della Valle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Nam, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vasili Karas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tad Gerlinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moucha CS, Weiser MC, Levin EJ. Current Strategies in Anesthesia and Analgesia for Total Knee Arthroplasty. J Am Acad Orthop Surg. 2016 Feb;24(2):60-73. doi: 10.5435/JAAOS-D-14-00259. Review.</citation>
    <PMID>26803543</PMID>
  </reference>
  <reference>
    <citation>Hannon CP, Keating TC, Lange JK, Ricciardi BF, Waddell BS, Della Valle CJ. Anesthesia and Analgesia Practices in Total Joint Arthroplasty: A Survey of the American Association of Hip and Knee Surgeons Membership. J Arthroplasty. 2019 Dec;34(12):2872-2877.e2. doi: 10.1016/j.arth.2019.06.055. Epub 2019 Jul 8.</citation>
    <PMID>31371038</PMID>
  </reference>
  <reference>
    <citation>Parvizi J, Miller AG, Gandhi K. Multimodal pain management after total joint arthroplasty. J Bone Joint Surg Am. 2011 Jun 1;93(11):1075-84. doi: 10.2106/JBJS.J.01095. Review.</citation>
    <PMID>21655901</PMID>
  </reference>
  <reference>
    <citation>Lex JR, Edwards TC, Packer TW, Jones GG, Ravi B. Perioperative Systemic Dexamethasone Reduces Length of Stay in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Arthroplasty. 2021 Mar;36(3):1168-1186. doi: 10.1016/j.arth.2020.10.010. Epub 2020 Oct 16.</citation>
    <PMID>33190999</PMID>
  </reference>
  <reference>
    <citation>Lunn TH, Kehlet H. Perioperative glucocorticoids in hip and knee surgery - benefit vs. harm? A review of randomized clinical trials. Acta Anaesthesiol Scand. 2013 Aug;57(7):823-34. doi: 10.1111/aas.12115. Epub 2013 Apr 15. Review.</citation>
    <PMID>23581549</PMID>
  </reference>
  <reference>
    <citation>Chen P, Li X, Sang L, Huang J. Perioperative intravenous glucocorticoids can decrease postoperative nausea and vomiting and pain in total joint arthroplasty: A meta-analysis and trial sequence analysis. Medicine (Baltimore). 2017 Mar;96(13):e6382. doi: 10.1097/MD.0000000000006382. Review.</citation>
    <PMID>28353565</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Craig J Della Valle, MD</investigator_full_name>
    <investigator_title>Professor of Orthopedic Surgery, Chief Division of Adult Reconstruction</investigator_title>
  </responsible_party>
  <keyword>dexamethasone</keyword>
  <keyword>opioid consumption</keyword>
  <keyword>postoperative pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

